MedTrace Logo

Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer

NCT07267247 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-12-05

No results posted yet for this study

Summary

This study investigated the incidence of cardiac dysfunction in patients with advanced or recurrent epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR- tyrosine kinase inhibitors.

Conditions

  • Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)
  • Drug-Related Side Effects and Adverse Reactions (MeSH Term)
  • Egfr Tyrosine Kinase Inhibitor
  • Cardiotoxicity

Interventions

DRUG

EGFR-TKI

Erlotinib, dacomitinib, afatinib, and osimertinib, with dose according to NCCN guide line.

OTHER

EGFR tyrosine kinase inhibitor

Erlotinib, dacomitinib, afatinib, and osimertinib, with dose according to NCCN guide line

Sponsors & Collaborators

  • Taichung Veterans General Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2024-04-30
Completion
2024-04-30
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07267247 on ClinicalTrials.gov